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Long-term evaluation of cardiovascular risk among 
diabetic patients has shown that the incidence of death due to 
myocardial infarction among these patients is 20%, whereas 
among nondiabetic patients it is only 3.5%. Such observa-
tions haveled to classifying diabetes as a risk that is equivalent 
to establi shed coronary artery disease.1 Among patients with 
established coronary artery disease, the presence of diabetes 
has been found to increase the fi ve-year mortality rate to more 
than twice what is seen for nondiabetic patients.2 The long-term 
outcome for patients with diabetes following revascularization 
is also adverse. Increased postprocedure mortality among angi-
oplasty patients with diabetes has been documented (3.2% versus
0.5%).3 Diabetes also confers a worse long-term outcome among 
patients undergoing bypass surgery. The Society of Thoracic Sur-
geons’ database shows that the surgical risk for diabetic patients 
is greater than for nondiabetic patients: 3.7% versus 2.7%, with 
greater risk for those requiring insulin.4 
Diabetes gives rise to a number of metabolic disturbances 
that result in progression of atherosclerosis and occurrence of 
cardiac events. The presence of hyperglycemia, abnormal lipid 
metabolism and insulin resistance, together with occurrences 
of hypertension, all result in acceleration of the atherosclerotic 
process. Increased oxidative stress results from decreased nitric 
oxide production, which is caused by altered endothelial cell 
function due to hyperglycemia.5 Release of free fatty acids from 
adipose tissue due to insulin resistance leads to oxidative stress
and decreased nitric oxide production.6 Increased endothelin 
production in diabetic patients also results in vasoconstriction. 
Platelet function is also altered in diabetes cases.7 Lipid abnor-
malities may result in elevated triglyceride levels with decreased 
high density lipoprotein (HDL) levels.8 Hypertension may be
associated with diabetes and renal dysfunction. Rapid progres-
sion of atherosclerosis and a greater tendency towards unstable
platelets result in cardiac events. 
Whenever a promising study does not produce the in-
tended solution, there is a tendency towards focusing it on a 
subgroup of more fragile patients, who are therefore more likely 
to respond well to the treatment in question. This happens 
particularly with studies on diabetes because of the destructive 
power of this disease in relation to vascular capability. Whereas 
physiopathological reasoning is elegant, its verifi cation is shaky. 
Thus, despite many studies of high methodological quality 
looking for the best evidence regarding the effectiveness of 
drug-eluting stents in coronary diseases among subgroups 
of diabetic patients,9-26 there have not been any data from ran-
domized controlled trials that could be used in meta-analyses. 
This seems to us to be a deliberate omission of data without 
statistical signifi cance, although some studies make reference 
to diabetes in their presentations of results. On the other hand, 
these trials have frequently presented separate comments refer-
ring to diabetic patients. 
A recently published systematic review27 compared drug-
eluting stents and bare-metal stents, and additionally compared 
sirolimus-eluting stents versus paclitaxel-eluting stents. Five aims 
were defi ned for the study, and stent type in relation to diabe-
tes was not among these aims, even though that review cited 
three studies28-30 in which 100% of the patients were diabetic. 
The discussion in that review makes contradictory statements 
regarding diabetic patients, while seeming to take a position in 
favor of bare-metal stents. 
To date, there has not been any evidence that drug-eluting 
stents are preferable for treating diabetic patients with coronary 
disease. The data omissions in the published studies make this 
statement clear. As can be seen from the main studies, there have 
not been any data supporting the effectiveness of drug-eluting 
stents and consequently their use as the preferential treatment 
for coronary disease in diabetic patients. Many revascularization 
results have been given without specifying whether the revascu-
larization was surgical or percutaneous. This lack of precision 
in defi ning outcomes has caused many misleading conclusions 
in the medical literature in this fi eld.
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